This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <a href="http://www.informaworld.com/smpp/title~content=t713597286">http://www.informaworld.com/smpp/title~content=t713597286</a>

# Activation of Spleen Lymphocytes by Plasmid DNA

E. Rykova<sup>a</sup>; P. Laktionov<sup>a</sup>; V. Vlassov<sup>a</sup>

<sup>a</sup> Institute of Bioorganic Chemistry, Siberian Division of Russian Academy of Sciences, Novosibirsk, Russia

**To cite this Article** Rykova, E. , Laktionov, P. and Vlassov, V.(1999) 'Activation of Spleen Lymphocytes by Plasmid DNA', Nucleosides, Nucleotides and Nucleic Acids, 18: 6, 1693 — 1695

To link to this Article: DOI: 10.1080/07328319908044825 URL: http://dx.doi.org/10.1080/07328319908044825

### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

#### ACTIVATION OF SPLEEN LYMPHOCYTES BY PLASMID DNA.

E. Rykova\*, P. Laktionov and V. Vlassov

Institute of Bioorganic Chemistry, Siberian Division of Russian Academy of Sciences, pr. Lavrentieva 8, Novosibirsk 630090, Russia

ABSTRACT. It was shown that plasmid pUC19 DNA stimulates in vitro proliferation of CBA mouse splenocytes in a dose-dependent manner. Stimulation effect of the plasmid DNA is additive with Con A or LPS, synergistic with PMA and is inhibited by nonimmunogenic phosphodiester oligonucleotides and Fab fragments of antimouse Ig antibodies. These data and the data of affinity labelling of ODN-binding proteins indicate that immunoglobulin receptors are involved in DNA-induced lymphocyte activation.

Bacterial DNA and certain oligonucleotides (ODNs) were shown to stimulate immune system and cause unspecific antitumor and antivirus effects <sup>1,2</sup>. These compounds induce T, B and natural killer cells to secrete several cytokines, increase splenic B cells number, class II major histocompatibility complex expression on B cells and immunoglobulin synthesis by splenocites *in vivo* and *in vitro* <sup>2,3</sup>.

We investigated here the stimulatory effect of plasmid pUC19 on splenocyte proliferation in vitro. pUC19 DNA was reported recently to have an adjuvant effect in gene-vaccinated animals, as well as in animals immunized with protein antigens<sup>3</sup>. We have shown that plasmid pUC19 DNA stimulates in vitro proliferation of CBA mouse splenocytes in a dose-dependent manner. Simultaneous treatment of the cells with the plasmid DNA and Con A or LPS produced an additive effect, while PMA acted synergistically with DNA. Nonimmunogenic phosphodiester oligonucleotides caused dose-dependent suppression of the DNA-induced lymphocyte proliferation. Monovalent Fab fragments of rabbit antimouse Ig antibodies (RAMIg) significantly inhibited plasmid

TABLE 1. Inhibition effect of anti-Ig antibodies and their Fab fragments on plasmid DNA-induced spleen lymphocyte proliferation. Mitogen and 50  $\mu$ g/ml anti-Ig antibodies or Fab fragments were added to cell suspension simultaneously. The results are the mean  $\pm$  SD of triplicate cultures and are representative of three separate experiments.

		[ <sup>3</sup> H]Thymidine incorporation, cpm·10 <sup>3</sup>		
Mitogens, concentration			+ anti-Ig	+ Fab
None		2.6 ±0.2	1.9 ±0.2	2.0 ±0.1
DNA,	10 μg/ml	$51.5 \pm 7.2$	$16.5 \pm 1.3$	$26.0 \pm 3.2$
DNA,	1 μg/ml	$41.0 \pm 4.5$	$9.0 \pm 1.1$	$11.0 \pm 1.4$
DNA,	0.1 μg/ml	$15.0 \pm 1.4$	$4.5 \pm 0.9$	$2.8 \pm 0.4$
LPS,	2.5 μg/ml	$42.0 \pm 5.1$	$20.0 \pm 3.5$	$35.0 \pm 4.2$




FIG. 1. Isolation of cellular IgM by immunoprecipitation with RAMIg antibodies from membrane-cytosole fractions (MCF) of CBA mouse spleen lymphocytes. Spleen lymphocytes (10<sup>6</sup>) were incubated with [<sup>32</sup>P]CIRp(N)<sub>16</sub>. Total MCF (lane 2) and immunoprecipitates of MCF with RAMIg antibodies, collected on protein A-Sepharose beads (lane 3) were analysed by 10-20% SDS PAGE, followed by autoradiography. Control of nonspecific binding was made with normal rabbit IgG instead of RAMIg (lane 4). Molecular weight markers: BSA and mouse myeloma IgG (lane 1), modified with [<sup>32</sup>P]CIRp(N)<sub>16</sub>.

DNA-induced polyclonal lymphocyte activation suggesting the involvement of Ig receptors in this process. In experiments with alkylating 4-[(N-2-chloroethyl-N-methyl)amino]benzylamine (ClR-) linked ODNs we have found that high molecular weight DNA prevents the modification of ODN- binding proteins. These data indicate that DNA and ODNs interact with the same splenocyte membrane proteins. Affinity modification of

lymphocytes membrane-cytosole proteins with a [32P]-labeled CIR-ODN resulted in labeling of 67-82 and 23 kDa polypeptides corresponding to IgD and IgM heavy and light chains respectively. The immunoglobulin nature of the 82 and 23 kDa oligonucleotide-binding polypeptides was confirmed by immunoprecipitation with RAMIg antibodies. These data indicate that immunoglobulin receptors are involved in DNA-induced lymphocyte activation.

### **REFERENCES**

- 1. Tokunaga, T., Yamamoto, H., Shimada. S., et al. Natl. Cancer Inst. 1984, 72, 955-962
- 2. Mojcik, C.F., Gourley, M.F., et al. Clin. Immunol. Immunopathol. 1993, 67, 130-136.
- 3. Krieg, A.M., Yi, A.-K., Matson, S., et al. Nature. 1995, 374, 546-549.